(HealthDay News) — Measurement of HbA1c at hospital admission can tailor treatment regimens at discharge, according to a study published in Diabetes Care.
Guillermo E. Umpierrez, MD, from Emory University in Atlanta, and colleagues conducted a prospective, multicenter open-label study to examine the safety and efficacy of a hospital discharge algorithm based on admission HbA1c.
Two hundred and twenty-four patients with HbA1c <7%; 7% to 9%; and >9% were discharged on their preadmission diabetes therapy; preadmission regimen plus glargine; and oral antidiabetes agents plus glargine or basal bolus regimen, respectively.
HbA1c was assessed at 12 weeks after hospital discharge.
The researchers found that HbA1c decreased from 8.7% at admission to 7.3% at 12 weeks of follow-up (P<.001). From baseline to 12 weeks, the change of HbA1c was −0.1% for patients with HbA1c <7%; −0.8% for patients with HbA1c of 7% to 9%; and −3.2% for patients with HbA1c of >9% (P<.001).
“Measurement of HbA1c on admission is beneficial in tailoring treatment regimens at discharge in general medicine and surgery patients with type 2 diabetes,” the researchers wrote.
Several authors disclosed financial ties to pharmaceutical companies, including Sanofi, which partially funded the study.